The MHRA is consulting on a proposal to make Acnecide Face 5% w/w Gel and Acnecide Face Wash 5% w/w Gel available from general sales outlets, but with more limited conditions of use than the current pharmacy products, following an application from the licence holder, Galderma UK Ltd..

The products contain 5% w/w of benzoyl peroxide N and are indicated for the treatment of mild acne in adults and adolescents aged 12 years and over.

Acnecide Face Gel and Acnecide Face Wash would be the first products containing benzoyl peroxide to be available as GSL medicines.

This deadline for responding to the consultation is 30 May 2019.